Ibrutinib-induced cardiomyopathy
The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Greater Baltimore Medical Center
2019-01-01
|
| Series: | Journal of Community Hospital Internal Medicine Perspectives |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20009666.2018.1555432 |